Source comparison
Thymosin Alpha-1 Vaccine Enhancement: Comparison Table
Healthy adults (influenza) 1:160 HAI titer 1:320 HAI titer 21 days 6–8 months Modest enhancement. Tα1 benefit greatest in immunocompromised groups Elderly (>65 years, influenza) 1:80 HAI titer 1:240 HAI titer 4–6 months Clinically significant. Addresses age-re
This comparison does not assign a generated winner or score.
- Healthy adults (influenza)
- 1:160 HAI titer
- 1:320 HAI titer
- 21 days
- 6–8 months
- Modest enhancement. Tα1 benefit greatest in immunocompromised groups
- Elderly (>65 years, influenza)
- 1:80 HAI titer
- 1:240 HAI titer
- 4–6 months
- Clinically significant. Addresses age-related immune senescence
- Hepatitis B non-responders
- 18% seroconversion
- 64% seroconversion
- 12 weeks
- 12–18 months
- Transformative outcome. Tα1 salvages failed vaccination attempts
- Cancer patients (post-chemotherapy)
- 40% protective titer
- 78% protective titer
- 28 days
- 3–5 months
- Essential adjunct. Restores vaccine efficacy in T-cell-depleted populations